How do you manage severe lenalidomide-associated drug rash in a transplant-eligible patient with multiple myeloma?  

Would your approach change based on the type of reaction (eg. Stevens-Johnson syndrome vs DRESS)?

How would you address maintenance (if any) post-transplant?

Would you consider pomalidomide for use in future lines of therapy?



Answer from: Medical Oncologist at Community Practice